UT Health San Antonio | The University of Texas Health Science Center at San Antonio

University awarded $12 million to further develop opioid use disorder drug

Charles  P.  France, PhD, to lead methocinnamox drug development program The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was awarded a $12 million cooperative agreement (U01) from the National Institutes of Health’s National Institute on Drug Abuse to further develop methocinnamox (MCAM) as a treatment for opioid use disorder. […]

Share This Story